推荐产品
等級
analytical standard
品質等級
產品線
VETRANAL®
儲存期限
limited shelf life, expiry date on the label
技術
HPLC: suitable
gas chromatography (GC): suitable
應用
forensics and toxicology
pharmaceutical (small molecule)
veterinary
格式
neat
儲存溫度
2-8°C
SMILES 字串
CC1=NC=C(C2=C(C3=CC=C(S(C)(=O)=O)C=C3)C=C(Cl)C=N2)C=C1
InChI
1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3
InChI 密鑰
MNJVRJDLRVPLFE-UHFFFAOYSA-N
基因資訊
human ... PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
相关类别
一般說明
依托考昔是一种非甾体类环加氧酶-2（COX-2）选择性抗炎药，主要用于骨关节炎和类风湿性关节炎患者的治疗。
應用
依托考昔已被用作参考标准品，用于通过液相色谱-串联质谱-常压化学电离分析法（LC-APCI/MS/MS）检测人血浆中的依托考昔。
有关合适仪器技术的更多信息，请参考产品′s分析证书。如需进一步支持，请联系技术服务。
法律資訊
VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany
訊號詞
Danger
危險聲明
危險分類
Acute Tox. 2 Dermal - Acute Tox. 4 Oral
儲存類別代碼
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
水污染物質分類（WGK）
WGK 3
其他客户在看
Rachel Clarke et al.
The Cochrane database of systematic reviews, (2)(2), CD004309-CD004309 (2009-04-17)
Etoricoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor prescribed for the relief of chronic pain in osteoarthritis and rheumatoid arthritis, and acute pain. The drug is believed to be associated with fewer upper gastrointestinal adverse effects than conventional non-steroidal anti-inflammatory drugs
Eugene R Viscusi et al.
Current medical research and opinion, 28(8), 1323-1335 (2012-06-29)
To evaluate the effects of two different doses of etoricoxib delivered perioperatively compared with placebo and standard pain management on pain at rest, pain with mobilization, and use of additional morphine/opioids postoperatively. In this double-blind, placebo-controlled, randomized clinical trial, we
Paola Patrignani et al.
Expert opinion on pharmacotherapy, 4(2), 265-284 (2003-02-04)
The development of COX2 inhibitors with improved biochemical selectivity (such as etoricoxib and valdecoxib) over that of commercially available coxibs has been driven by the potential advantage of safety using higher coxib doses for increased efficacy. Etoricoxib has been approved
Rik J Lories
Expert opinion on drug metabolism & toxicology, 8(12), 1599-1608 (2012-11-07)
Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line therapies in the management of patients with ankylosing spondylitis. This chronic inflammatory skeletal disorder, a subtype of spondyloarthritis, is characterized by inflammatory back pain and affects young adults causing important suffering and disability. Long-term
Rachel Clarke et al.
The Cochrane database of systematic reviews, 4(4), CD004309-CD004309 (2012-04-20)
Etoricoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor licensed for the relief of chronic pain in osteoarthritis and rheumatoid arthritis, and acute pain in some jurisdictions. This class of drugs is believed to be associated with fewer upper gastrointestinal adverse effects
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门